Psoriasis: conceptos actuales en el tratamiento sistémico.
Parte 1: Agentes sistémicos tradicionales
Palabras clave:
psoriasis, tratamiento con metotrexato, ciclosporina, acitretino, fototerapiaResumen
La psoriasis es una dermatosis en la que intervienen múltiples factores patogé- nicos que interactúan de forma compleja. En la primera parte de este artículo, y a la luz de los conceptos actuales, se revisan los tratamientos sistémicos tradicionales empleados para el manejo de esta entidad.
Biografía del autor/a
Francisco Alejandro Arango
Médico residente de dermatología segundo año, Universidad de Caldas.
Mario Fernando Franco
Médico residente de dermatología segundo año, Universidad de Caldas
Ana María Hoyos
Médica dermatóloga. Profesora catedrática postgrado dermatología, Universidad de Caldas.
Referencias bibliográficas
1. De Jager ME, De Jong EM, van de Kerkhof PC, Seyger MM. Efficacy and safety of treatments for childhood psoriasis: A systematic literature review. J Am Acad Dermatol. 2010;62:1013-30.
2. Ferrándiz C, Carrascosa JM, Boada A. A new era in the management of psoriasis? The biologics: Facts and controversies. Clin Dermatol. 2010;28:81-7.
3. Hüffmeier U, Lascorz J, Becker T, Schürmeier-Horst F, Magener A, Ekici AB, et al. Characterization of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1. J Med Genet. 2009;46:736-44.
4. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496-509.
5. Mrowietz U, Reich K. Psoriasis –new insights into pathogenesis and treatment. Dtsch Arztebl Int. 2009;106:11-8.
6. Homey B, Meller S. Chemokines and other mediators as therapeutic targets in psoriasis vulgaris. Clin Dermatol. 2008;26:539-45.
7. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol. 2008;128:1064-7.
8. Kimball AB, Kupper TS. Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. Clin Dermatol. 2008;26:554-61.
9. Woodley DT, Kim GH. Potential new insight into the pathogenesis of psoriasis. Arch Dermatol. 2009;145:713-4.
10. Henning W, Kaufman R. Fisiopatología de la psoriasis. En: Henning W, Kaufman R. Tratamiento de la psoriasis basado en la evidencia: centrado en los biológicos. 1 edición. Dinamarca: Uni-Med Science; 2009. p. 25-38.
11. Farkas A, Kemény L. Psoriasis and alcohol: Is cutaneous ethanol one of the missing links? Br J Dermatol. 2010;162:711-6.
12. Lebwohl M, van de Kerkhof P. Psoriasis. En: Lebwohl M, Heymann W, Jones J, Coulson I. Treatment of skin disease. Third edition.: Saunders-Elsevier; 2010. p. 626-36.
13. Menter A, Korman NJ, Elmets C, Feldman S, Gelfand J, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62:114
14. Matz H. Phototherapy for psoriasis. What to choose and how to use: Facts and controversies. Clin Dermatol. 2010;28:73-80
15. Jeffes EW III, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Liu G, et al. Methotrexate therapy of psoriasis: Differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol. 1995;104:183-8..
16. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451-85.
17. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol. 2005;53:652-9.
18. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, ReitsmaJB, Goldschmidt WF, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349:658-65.
19. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab Vs. methotrexate Vs.placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558-66.
20. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation consensus conference. J Am Acad Dermatol. 2009;60:824-37.
21. Cohn DL, O’Brien RJ, Geiter LJ, Gordin FM, Hershfield E, Horsburgh RC, et al. Targeted tuberculin testing and treatment of latent tuberculosis infection. Fecha de consulta: 18 de agosto de 2010. Disponible en: http://www.cdc.gov/ mmwr/preview/mmwrhtml/rr4906a1.htm.
22. Gottlieb AB, Grossman RM, Khandke L, Carter DM, Sehgal PB, Fu SM, et al. Studies of the effect of cyclosporine in psoriasis in vivo: Combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992;98:302-9.
23. Prens EP, van Joost T, Hegmans JP, Hooft-Benne K, Ysselmuiden OE, Benner R. Effects of cyclosporine on cytokines and cytokine receptors in psoriasis. J Am Acad Dermatol. 1995;33:947-53.
24. Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris. Arch Dermatol Res. 2007;299:111-38.
25. Food and Drug Administration (FDA). Cyclosporin FDA package insert. Fecha de consulta: 18 de agosto de 2010. Disponible en: http://www.accessdata.fda.gov/ Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search. Overview&DrugName=CYCLOSPORINE.
26. Mrowietz U, Farber L, Henneicke-von Zepelin HH, Bachmann H, Welzel D, Christophers E. Long-term maintenance therapy with cyclosporine and post-treatment survey in severe psoriasis: Results of a multicenter study; German multicenter study. J Am Acad Dermatol. 1995;33:470-5.
27. Berth-Jones J. The use of cyclosporin in psoriasis. J Dermatolog Treat. 2005;16:258-77.
28. Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: Effects on renal function and structure. J Am Acad Dermatol. 1996;35:710-9.
29. Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporin induced hypertension: Incidence, pathogenesis and management. Drug Saf. 1999;20:437-49.
30. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and cyclosporin: Nested cohort crossover study. Lancet. 2001;358:1042-5.
31. Berth-Jones J. The use of cyclosporin in psoriasis. J Dermatolog Treat. 2005;16:258-77.
32. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, et al. Cyclosporine consensus conference: With emphasis on the treatment of psoriasis. J Am Acad Dermatol. 1998;39:464-75.
33. Fernández JM, Armario JC. Retinoides en dermatología. Med Cutan Iber Lat Am. 2003;31:271-94.
34. Goldfarb MT, Ellis CN, Gupta AK, Tincoff T, Hamilton TA, Voorhees JJ. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol. 1988;18:655-62.
35. Geiger JM. Efficacy of acitretin in severe psoriasis. Skin Therapy Lett. 2003;8:1-7.
36. Ozawa A, Ohkido M, Haruki Y, Kobayashi H, Ohkawara A, Ohno Y, et al. Treatments of generalized pustular psoriasis: A multicenter study in Japan. J Dermatol 1999;26:141-9.
37. Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol. 1997;133:711-5.
38. David M, Hodak E, Lowe NJ. Adverse effects of retinoids. Med Toxicol Adverse Drug Exp. 1988;3:273-88.
39. Berbis P, Bun H, Geiger JM, Rognin C, Durand A, Serradimigni A, et al. Acitretin (RO10-1670) and oral contraceptives: Interaction study. Arch Dermatol Res. 1988;280:388-9.
40. Zhang XB, Luo Q, Li CX, He YQ, Xu X. Clinical investigation of acitretin in children with severe inherited keratinization disorders in China. J Dermatolog Treat. 2008;19:221-8.
41. Katugampola RP, Finlay AY. Oral retinoid therapy for disorders of keratinization: Single-centre retrospective 25 years’ experience on 23 patients. Br J of Dermatol. 2006;154:267-76.
2. Ferrándiz C, Carrascosa JM, Boada A. A new era in the management of psoriasis? The biologics: Facts and controversies. Clin Dermatol. 2010;28:81-7.
3. Hüffmeier U, Lascorz J, Becker T, Schürmeier-Horst F, Magener A, Ekici AB, et al. Characterization of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1. J Med Genet. 2009;46:736-44.
4. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496-509.
5. Mrowietz U, Reich K. Psoriasis –new insights into pathogenesis and treatment. Dtsch Arztebl Int. 2009;106:11-8.
6. Homey B, Meller S. Chemokines and other mediators as therapeutic targets in psoriasis vulgaris. Clin Dermatol. 2008;26:539-45.
7. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol. 2008;128:1064-7.
8. Kimball AB, Kupper TS. Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. Clin Dermatol. 2008;26:554-61.
9. Woodley DT, Kim GH. Potential new insight into the pathogenesis of psoriasis. Arch Dermatol. 2009;145:713-4.
10. Henning W, Kaufman R. Fisiopatología de la psoriasis. En: Henning W, Kaufman R. Tratamiento de la psoriasis basado en la evidencia: centrado en los biológicos. 1 edición. Dinamarca: Uni-Med Science; 2009. p. 25-38.
11. Farkas A, Kemény L. Psoriasis and alcohol: Is cutaneous ethanol one of the missing links? Br J Dermatol. 2010;162:711-6.
12. Lebwohl M, van de Kerkhof P. Psoriasis. En: Lebwohl M, Heymann W, Jones J, Coulson I. Treatment of skin disease. Third edition.: Saunders-Elsevier; 2010. p. 626-36.
13. Menter A, Korman NJ, Elmets C, Feldman S, Gelfand J, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62:114
14. Matz H. Phototherapy for psoriasis. What to choose and how to use: Facts and controversies. Clin Dermatol. 2010;28:73-80
15. Jeffes EW III, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Liu G, et al. Methotrexate therapy of psoriasis: Differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol. 1995;104:183-8..
16. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451-85.
17. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol. 2005;53:652-9.
18. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, ReitsmaJB, Goldschmidt WF, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349:658-65.
19. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab Vs. methotrexate Vs.placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558-66.
20. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation consensus conference. J Am Acad Dermatol. 2009;60:824-37.
21. Cohn DL, O’Brien RJ, Geiter LJ, Gordin FM, Hershfield E, Horsburgh RC, et al. Targeted tuberculin testing and treatment of latent tuberculosis infection. Fecha de consulta: 18 de agosto de 2010. Disponible en: http://www.cdc.gov/ mmwr/preview/mmwrhtml/rr4906a1.htm.
22. Gottlieb AB, Grossman RM, Khandke L, Carter DM, Sehgal PB, Fu SM, et al. Studies of the effect of cyclosporine in psoriasis in vivo: Combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992;98:302-9.
23. Prens EP, van Joost T, Hegmans JP, Hooft-Benne K, Ysselmuiden OE, Benner R. Effects of cyclosporine on cytokines and cytokine receptors in psoriasis. J Am Acad Dermatol. 1995;33:947-53.
24. Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris. Arch Dermatol Res. 2007;299:111-38.
25. Food and Drug Administration (FDA). Cyclosporin FDA package insert. Fecha de consulta: 18 de agosto de 2010. Disponible en: http://www.accessdata.fda.gov/ Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search. Overview&DrugName=CYCLOSPORINE.
26. Mrowietz U, Farber L, Henneicke-von Zepelin HH, Bachmann H, Welzel D, Christophers E. Long-term maintenance therapy with cyclosporine and post-treatment survey in severe psoriasis: Results of a multicenter study; German multicenter study. J Am Acad Dermatol. 1995;33:470-5.
27. Berth-Jones J. The use of cyclosporin in psoriasis. J Dermatolog Treat. 2005;16:258-77.
28. Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: Effects on renal function and structure. J Am Acad Dermatol. 1996;35:710-9.
29. Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporin induced hypertension: Incidence, pathogenesis and management. Drug Saf. 1999;20:437-49.
30. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and cyclosporin: Nested cohort crossover study. Lancet. 2001;358:1042-5.
31. Berth-Jones J. The use of cyclosporin in psoriasis. J Dermatolog Treat. 2005;16:258-77.
32. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, et al. Cyclosporine consensus conference: With emphasis on the treatment of psoriasis. J Am Acad Dermatol. 1998;39:464-75.
33. Fernández JM, Armario JC. Retinoides en dermatología. Med Cutan Iber Lat Am. 2003;31:271-94.
34. Goldfarb MT, Ellis CN, Gupta AK, Tincoff T, Hamilton TA, Voorhees JJ. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol. 1988;18:655-62.
35. Geiger JM. Efficacy of acitretin in severe psoriasis. Skin Therapy Lett. 2003;8:1-7.
36. Ozawa A, Ohkido M, Haruki Y, Kobayashi H, Ohkawara A, Ohno Y, et al. Treatments of generalized pustular psoriasis: A multicenter study in Japan. J Dermatol 1999;26:141-9.
37. Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol. 1997;133:711-5.
38. David M, Hodak E, Lowe NJ. Adverse effects of retinoids. Med Toxicol Adverse Drug Exp. 1988;3:273-88.
39. Berbis P, Bun H, Geiger JM, Rognin C, Durand A, Serradimigni A, et al. Acitretin (RO10-1670) and oral contraceptives: Interaction study. Arch Dermatol Res. 1988;280:388-9.
40. Zhang XB, Luo Q, Li CX, He YQ, Xu X. Clinical investigation of acitretin in children with severe inherited keratinization disorders in China. J Dermatolog Treat. 2008;19:221-8.
41. Katugampola RP, Finlay AY. Oral retinoid therapy for disorders of keratinization: Single-centre retrospective 25 years’ experience on 23 patients. Br J of Dermatol. 2006;154:267-76.
Cómo citar
1.
Arango FA, Franco MF, Hoyos AM. Psoriasis: conceptos actuales en el tratamiento sistémico.: Parte 1: Agentes sistémicos tradicionales. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 6 de marzo de 2019 [citado 18 de abril de 2024];19(1):35-42. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/384
Descargas
Los datos de descargas todavía no están disponibles.
Descargas
Publicado
2019-03-06
Cómo citar
1.
Arango FA, Franco MF, Hoyos AM. Psoriasis: conceptos actuales en el tratamiento sistémico.: Parte 1: Agentes sistémicos tradicionales. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 6 de marzo de 2019 [citado 18 de abril de 2024];19(1):35-42. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/384
Número
Sección
Artículo de revisión
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | |
| Vistas de PDF | |
| Descargas de PDF | |
| Vistas de HTML | |
| Otras vistas | |
